Skip to main content

Advertisement

SpringerLink
Log in

Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Immunotoxins are fusion proteins that combine a targeting component such as an antibody fragment or ligand with a cytotoxic effector component that induces apoptosis in specific cell populations displaying the corresponding antigen or receptor. Human cytolytic fusion proteins (hCFPs) are less immunogenic than conventional immunotoxins because they contain human pro-apoptotic enzymes as effectors. However, one drawback of hCFPs is that target cells can protect themselves by expressing endogenous inhibitor proteins. Inhibitor-resistant enzyme mutants that maintain their cytotoxic activity are therefore promising effector domain candidates. We recently developed potent variants of the human ribonuclease angiogenin (Ang) that were either more active than the wild-type enzyme or less susceptible to inhibition because of their lower affinity for the ribonuclease inhibitor RNH1. However, combining the mutations was unsuccessful because although the enzyme retained its higher activity, its susceptibility to RNH1 reverted to wild-type levels. We therefore used molecular dynamic simulations to determine, at the atomic level, why the affinity for RNH1 reverted, and we developed strategies based on the introduction of further mutations to once again reduce the affinity of Ang for RNH1 while retaining its enhanced activity. We were able to generate a novel Ang variant with remarkable in vitro cytotoxicity against HL-60 cells and pro-inflammatory macrophages. We also demonstrated the pro-apoptotic potential of Ang-based hCFPs on cells freshly isolated from leukemia patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Abbreviations

AML:

Acute myeloid leukemia

Ang:

Angiogenin

CMML:

Chronic myelomonocytic leukemia

DNA:

Deoxyribonucleic acid

EC50 :

Half maximal effective concentration

Gb:

Granzyme B

GFP:

Green fluorescent protein

hCFP:

Human cytolytic fusion protein

hIFNγ:

Human interferon gamma

hM1Φ:

Human pro-inflammatory macrophages

HEK293T:

Human embryonic kidney cells

IMAC:

Immobilized metal ion affinity chromatography

K i :

Inhibitory constant

MOG:

Myelin oligodendrocyte glycoprotein

PBMC:

Peripheral blood mononuclear cell

PCR:

Polymerase chain reaction

PI:

Propidium iodide

RNA:

Ribonucleic acid

RNH1:

Ribonuclease/angiogenin inhibitor 1

RPMI:

Roswell Park Memorial Institute

SEM:

Standard error of the mean

SOE:

Splicing by overlap extension

tRNA:

Transfer RNA

tiRNA:

tRNA-derived stress-induced RNA

XTT:

2,3-bis-(2-Methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide

References

  1. Weidle UH, Georges G, Brinkmann U (2012) Fully human targeted cytotoxic fusion proteins: new anticancer agents on the horizon. Cancer Genomics Proteomics 9:119–133

    CAS  PubMed  Google Scholar 

  2. Monti DM, D’Alessio G (2004) Cytosolic RNase inhibitor only affects RNases with intrinsic cytotoxicity. J Biol Chem 279:39195–39198. doi:10.1074/jbc.C400311200

    Article  CAS  PubMed  Google Scholar 

  3. Leland PA, Raines RT (2001) Cancer chemotherapy–ribonucleases to the rescue. Chem Biol 8:405–413

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Rutkoski TJ, Raines RT (2008) Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity. Curr Pharm Biotechnol 9:185–189

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Cremer C, Vierbuchen T, Hein L et al (2015) Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potential. J Immunother 38:85–95. doi:10.1097/CJI.0000000000000053

    Article  CAS  PubMed  Google Scholar 

  6. Czech A, Wende S, Morl M et al (2013) Reversible and rapid transfer-RNA deactivation as a mechanism of translational repression in stress. PLoS Genet 9:e1003767. doi:10.1371/journal.pgen.1003767

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Pizzo E, Sarcinelli C, Sheng J et al (2013) Ribonuclease/angiogenin inhibitor 1 regulates stress-induced subcellular localization of angiogenin to control growth and survival. J Cell Sci 126:4308–4319. doi:10.1242/jcs.134551

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Russo N, Shapiro R, Acharya KR et al (1994) Role of glutamine-117 in the ribonucleolytic activity of human angiogenin. Proc Natl Acad Sci USA 91:2920–2924

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Chen CZ, Shapiro R (1999) Superadditive and subadditive effects of “hot spot” mutations within the interfaces of placental ribonuclease inhibitor with angiogenin and ribonuclease A. Biochemistry 38:9273–9285. doi:10.1021/bi990762a

    Article  CAS  PubMed  Google Scholar 

  10. Chen CZ, Shapiro R (1997) Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A. Proc Natl Acad Sci USA 94:1761–1766

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Acharya KR, Shapiro R, Allen SC et al (1994) Crystal structure of human angiogenin reveals the structural basis for its functional divergence from ribonuclease. Proc Natl Acad Sci USA 91:2915–2919

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Leonidas DD, Shapiro R, Subbarao GV et al (2002) Crystallographic studies on the role of the C-terminal segment of human angiogenin in defining enzymatic potency. Biochemistry 41:2552–2562

    Article  CAS  PubMed  Google Scholar 

  13. de Kruif J, Tijmensen M, Goldsein J et al (2000) Recombinant lipid-tagged antibody fragments as functional cell-surface receptors. Nat Med 6:223–227. doi:10.1038/72339

    Article  PubMed  Google Scholar 

  14. Graziano RF, Tempest PR, White P et al (1995) Construction and characterization of a humanized anti-gamma-Ig receptor type I (Fc gamma RI) monoclonal antibody. J Immunol 155:4996–5002

    CAS  PubMed  Google Scholar 

  15. Ho SN, Hunt HD, Horton RM et al (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51–59

    Article  CAS  PubMed  Google Scholar 

  16. Stocker M, Tur MK, Sasse S et al (2003) Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expr Purif 28:211–219

    Article  CAS  PubMed  Google Scholar 

  17. Gallagher R, Collins S, Trujillo J et al (1979) Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 54:713–733

    CAS  PubMed  Google Scholar 

  18. Diehl V, Kirchner HH, Schaadt M et al (1981) Hodgkin’s disease: establishment and characterization of four in vitro cell lies. J Cancer Res Clin Oncol 101:111–124

    Article  CAS  PubMed  Google Scholar 

  19. Schiffer S, Hristodorov D, Mladenov R et al (2013) Species-dependent functionality of the human cytolytic fusion proteins granzyme B-H22(scFv) and H22(scFv)-angiogenin in macrophages. Antibodies 2:9–18

    Article  CAS  Google Scholar 

  20. Kampmeier F, Ribbert M, Nachreiner T et al (2009) Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-alkylguanine DNA alkyltransferase. Bioconjug Chem 20:1010–1015. doi:10.1021/bc9000257

    Article  CAS  PubMed  Google Scholar 

  21. Niesen J, Stein C, Brehm H et al (2015) Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities. J Cancer Res Clin Oncol. doi:10.1007/s00432-015-1975-5

    Google Scholar 

  22. Nachreiner T, Kampmeier F, Thepen T et al (2008) Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin. J Neuroimmunol 195:28–35. doi:10.1016/j.jneuroim.2008.01.001

    Article  CAS  PubMed  Google Scholar 

  23. Ribbert T, Thepen T, Tur MK et al (2010) Recombinant, ETA′-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice. Br J Dermatol 163:279–286. doi:10.1111/j.1365-2133.2010.09824.x

    Article  CAS  PubMed  Google Scholar 

  24. Stöcker M, Pardo A, Hetzel C et al (2008) Eukaryotic expression and secretion of EGFP-labeled annexin A5. Protein Expr Purif 58:325–331. doi:10.1016/j.pep.2007.12.009

    Article  PubMed  Google Scholar 

  25. Verhoven B, Schlegel RA, Williamson P (1995) Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J Exp Med 182:1597–1601

    Article  CAS  PubMed  Google Scholar 

  26. Krauss J, Arndt MA, Vu BK et al (2005) Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme. Br J Haematol 128:602–609. doi:10.1111/j.1365-2141.2005.05356.x

    Article  CAS  PubMed  Google Scholar 

  27. Arndt MA, Krauss J, Vu BK et al (2005) A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cells. J Immunother 28:245–251

    Article  CAS  PubMed  Google Scholar 

  28. Hendrzak JA, Wallace PK, Morahan PS (1994) Optimizing the detection of cell surface antigens on elicited or activated mouse peritoneal macrophages. Cytometry 17:349–356. doi:10.1002/cyto.990170412

    Article  CAS  PubMed  Google Scholar 

  29. Leonidas DD, Shapiro R, Allen SC et al (1999) Refined crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth. J Mol Biol 285:1209–1233. doi:10.1006/jmbi.1998.2378

    Article  CAS  PubMed  Google Scholar 

  30. Dickson KA, Kang DK, Kwon YS et al (2009) Ribonuclease inhibitor regulates neovascularization by human angiogenin. Biochemistry 48:3804–3806. doi:10.1021/bi9005094

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Stahnke B, Thepen T, Stocker M et al (2008) Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther 7:2924–2932. doi:10.1158/1535-7163.MCT-08-0554

    Article  CAS  PubMed  Google Scholar 

  32. Schiffer S, Letzian S, Jost E et al (2013) Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells. Cancer Lett 341:178–185. doi:10.1016/j.canlet.2013.08.005

    Article  CAS  PubMed  Google Scholar 

  33. Dunphy CH, Tang W (2007) The value of CD64 expression in distinguishing acute myeloid leukemia with monocytic differentiation from other subtypes of acute myeloid leukemia: a flow cytometric analysis of 64 cases. Arch Pathol Lab Med 131:748–754. doi:10.1043/1543-2165(2007)131[748:TVOCEI]2.0.CO;2

    CAS  PubMed  Google Scholar 

  34. Santos IM, Franzon CM, Koga AH (2012) Laboratory diagnosis of chronic myelomonocytic leukemia and progression to acute leukemia in association with chronic lymphocytic leukemia: morphological features and immunophenotypic profile. Rev Bras Hematol Hemoter 34:242–244. doi:10.5581/1516-8484.20120058

    Article  PubMed Central  PubMed  Google Scholar 

  35. Schiffer S, Rosinke R, Jost E et al (2014) Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins. Int J Cancer 135:1497–1508. doi:10.1002/ijc.28786

    Article  CAS  PubMed  Google Scholar 

  36. Karehed K, Dimberg A, Dahl S et al (2007) IFN-gamma-induced upregulation of Fcgamma-receptor-I during activation of monocytic cells requires the PKR and NFkappaB pathways. Mol Immunol 44:615–624. doi:10.1016/j.molimm.2006.01.013

    Article  CAS  PubMed  Google Scholar 

  37. Wei H, Bera TK, Wayne AS et al (2013) A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene. J Biol Chem 288:12305–12312. doi:10.1074/jbc.M113.461343

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Conway O’Brien E, Prideaux S, Chevassut T (2014) The epigenetic landscape of acute myeloid leukemia. Adv Hematol. 2014:103175. doi:10.1155/2014/103175

    PubMed Central  PubMed  Google Scholar 

  39. Jankowska AM, Makishima H, Tiu RV et al (2011) Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 118:3932–3941. doi:10.1182/blood-2010-10-311019

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Schnerch D, Yalcintepe J, Schmidts A et al (2012) Cell cycle control in acute myeloid leukemia. Am J Cancer Res 2:508–528

    PubMed Central  PubMed  Google Scholar 

  41. Scholl C, Gilliland DG, Frohling S (2008) Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 35:336–345. doi:10.1053/j.seminoncol.2008.04.004

    Article  CAS  PubMed  Google Scholar 

  42. Gao X, Xu Z (2008) Mechanisms of action of angiogenin. Acta Biochim Biophys Sin (Shanghai) 40:619–624

    Article  CAS  Google Scholar 

  43. Lu Z, Xu S (2006) ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 58:621–631. doi:10.1080/15216540600957438

    Article  CAS  PubMed  Google Scholar 

  44. Peng Y, Li L, Huang M et al (2014) Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells. Cell Signal 26:2782–2792. doi:10.1016/j.cellsig.2014.08.021

    Article  CAS  PubMed  Google Scholar 

  45. Sadagopan S, Veettil MV, Chakraborty S et al (2012) Angiogenin functionally interacts with p53 and regulates p53-mediated apoptosis and cell survival. Oncogene 31:4835–4847. doi:10.1038/onc.2011.648

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Ivanov P, Emara MM, Villen J et al (2011) Angiogenin-induced tRNA fragments inhibit translation initiation. Mol Cell 43:613–623. doi:10.1016/j.molcel.2011.06.022

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This project was funded by the Deutsche Forschungsgemeinschaft (DFG). The authors would like to thank Dr. Christoph Stein (Institute for Applied Medical Engineering, University Hospital RWTH Aachen/Fraunhofer Institute for Molecular Biology and Applied Ecology, Department of Pharmaceutical Product Development, Aachen) for helpful discussions on leukemia specimen handling, Judith Niesen (Fraunhofer Institute for Molecular Biology and Applied Ecology, Department of Pharmaceutical Product Development, Aachen) for providing the fusion protein 2112(scFv)-Ang GGRRmut, Anh-Tuah Pham (Institute for Applied Medical Engineering, University Hospital RWTH Aachen) for providing her2(scFv)-Ang GGRRmut and Fanny Frenzel (University Hospital RWTH Aachen, Department of Hematology and Oncology, Internal Medicine IV, Aachen, Germany) for providing patient data and specimens. Finally, we are very grateful to Dr. Richard M Twyman for critically reading this manuscript. Radoslav Mladenov was supported by a scholarship from the Jürgen Manchot Foundation.

Author information

Author notes

    Authors and Affiliations

    1. Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, University Hospital RWTH Aachen, Pauwelsstr. 20, 52074, Aachen, Germany

      Christian Cremer, Hanna Braun, Lea Schenke, Stefan Barth & Thomas Nachreiner

    2. Department of Computational Biophysics, German Research School for Simulation Sciences (Joint Venture of RWTH Aachen University and Forschungszentrum Jülich), 52428, Jülich, Germany

      Xiaojing Cong & Paolo Carloni

    3. Institute for Advanced Simulations IAS-5, Computational Biomedicine, Forschungszentrum, Jülich, Germany

      Xiaojing Cong & Paolo Carloni

    4. Department of Pharmaceutical Product Development, Fraunhofer Institute for Molecular Biology and Applied Ecology, Forckenbeckstr. 6, 52074, Aachen, Germany

      Radoslav Mladenov & Rainer Fischer

    5. Department of Hematology and Oncology (Internal Medicine IV), University Hospital RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Germany

      Edgar Jost & Tim H. Brümmendorf

    6. Institute for Molecular Biotechnology, RWTH Aachen University, Worringer Weg 1, 52074, Aachen, Germany

      Rainer Fischer

    7. South African Research Chair in Cancer Biotechnology, Institute of Infectious Disease and Molecular Medicine (IDM), Anzio Road, Observatory, Cape Town, 7925, South Africa

      Stefan Barth

    8. Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town, 7925, South Africa

      Stefan Barth

    Authors
    1. Christian Cremer
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Hanna Braun
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Radoslav Mladenov
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Lea Schenke
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Xiaojing Cong
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Edgar Jost
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Tim H. Brümmendorf
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Rainer Fischer
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Paolo Carloni
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Stefan Barth
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. Thomas Nachreiner
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Thomas Nachreiner.

    Ethics declarations

    Conflict of interest

    The authors have no conflict of interest to disclose.

    Additional information

    Stefan Barth and Thomas Nachreiner contributed equally to this manuscript.

    Electronic supplementary material

    Below is the link to the electronic supplementary material.

    Supplementary material 1 (PDF 239 kb)

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Cremer, C., Braun, H., Mladenov, R. et al. Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo. Cancer Immunol Immunother 64, 1575–1586 (2015). https://doi.org/10.1007/s00262-015-1763-8

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00262-015-1763-8

    Keywords

    Search

    Navigation